As this happened, Ladenburg Thalmann upgraded its Evaxion Biotech A/S ADR [EVAX] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating.
Price Performance Review of EVAX
On Tuesday, Evaxion Biotech A/S ADR [NASDAQ:EVAX] saw its stock jump 36.25% to $3.27. Over the last five days, the stock has lost -25.17%. Evaxion Biotech A/S ADR shares have fallen nearly -22.64% since the year began. Nevertheless, the stocks have fallen -85.78% over the past one year. While a 52-week high of $23.70 was reached on 01/24/25, a 52-week low of $2.22 was recorded on 02/03/25. SMA at 50 days reached $5.11, while 200 days put it at $12.89.
Levels Of Support And Resistance For EVAX Stock
The 24-hour chart illustrates a support level at 2.78, which if violated will result in even more drops to 2.30. On the upside, there is a resistance level at 3.90. A further resistance level may holdings at 4.54. The Relative Strength Index (RSI) on the 14-day chart is 44.10, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.78, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.15%. Stochastics %K at 6.05% indicates the stock is a buying.
How much short interest is there in Evaxion Biotech A/S ADR?
A steep rise in short interest was recorded in Evaxion Biotech A/S ADR stocks on 2025-01-15, growing by 78112.0 shares to a total of 0.1 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 24211.0 shares. There was a rise of 76.34%, which implies that there is a positive sentiment for the stock.
